The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
By 2030, How Much Growth In Market Size Is Expected For The Neurological Disorder Drugs Market?
The market for neurological disorder drugs has seen robust expansion in recent times. This market is projected to expand from $89.24 billion in 2025 to $94.49 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.9%. Factors contributing to its historical growth include an increasing incidence of epilepsy and neurodegenerative conditions, an aging worldwide populace, the extended application of symptomatic neurological medications, the broadening of hospital-based neurological services, and higher rates of neurological disorder diagnoses.
The market for neurological disorder drugs is projected to experience robust expansion in the coming years. Its valuation is set to reach $116.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This anticipated growth throughout the forecast period stems from various factors, including progress in neurological drug development pipelines, the increasing prevalence of Alzheimer’s and Parkinson’s diseases, enhanced availability of neurological care in developing markets, a growing need for tailored neurology treatments, and the wider availability of homecare and outpatient neurological therapies. Key trends during this period encompass the increasing uptake of disease-modifying neurological treatments, a heightened emphasis on prompt diagnosis and sustained disease management, an escalating requirement for combination drug therapies, the broadening scope of oral and home-based neurological interventions, and a stronger focus on managing symptoms and enhancing the quality of life for patients.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp
Which Growth Factors Are Strengthening The Neurological Disorder Drugs Market Landscape?
The rising occurrence of neurological conditions is anticipated to boost the expansion of the neurological disorder drugs market in the future. Neurological disorders are defined as ailments impacting the brain, spinal cord, and nerves, stemming from structural, biochemical, or electrical irregularities, which result in diverse symptoms. The increase in neurological illnesses is linked to the worldwide aging population and heightened exposure to environmental, metabolic, and lifestyle risk elements. Medications for neurological disorders are crucial in managing these intricate conditions, providing symptom alleviation, retarding disease advancement, and enhancing long-term patient prognoses. As an illustration, in September 2024, data from the Australian Institute of Health and Welfare, a government body based in Australia, indicates that the population suffering from dementia in Australia is predicted to more than double between 2023 and 2058, increasing from approximately 411,100 in 2023 to 849,300 by 2058, affecting about 315,500 men and 533,800 women. Consequently, the expanding incidence of neurological ailments is fueling the growth of the neurological disorder drugs market.
Which Segment-Based Categories Are Covered In The Neurological Disorder Drugs Market?
The neurological disorder drugs market covered in this report is segmented –
1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes
2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users
Subsegments:
1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine
2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists
3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics
4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic
5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications
Which Trends Are Expected To Shape The Neurological Disorder Drugs Market?
Leading companies in the neurological disorder drugs market are focusing on developing innovative solutions, such as Ocrelizumab-based therapies, to enhance treatment efficacy, improve patient outcomes, and expand therapeutic options for individuals with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody designed to target CD20-positive B cells, helping reduce disease activity and slow progression in both relapsing and primary progressive forms of multiple sclerosis. For instance, in September 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, received regulatory approval from the U.S. Food and Drug Administration (FDA) for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq), a twice-yearly, approximately 10-minute subcutaneous injection, marking the first-ever subcutaneous Ocrevus formulation approved for both relapsing (RMS) and primary progressive (PPMS) multiple sclerosis. This enhanced delivery option is designed to improve convenience, expand access to therapy, and support clinical workflow efficiency by offering a faster, non-intravenous method of administration.
Who Are The Businesses Driving Activity In The Neurological Disorder Drugs Market?
Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.
Access The Complete Neurological Disorder Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report
Which Region Holds The Largest Share In The Neurological Disorder Drugs Market?
North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Neurological Disorder Drugs Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp
Browse Through More Reports Similar to the Global Neurological Disorder Drugs Market 2026, By The Business Research Company
Neurological Disorder Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report
Central Nervous System Drug Market Report 2026
https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report
Cholinergic Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model